The Current and Future Landscape of SERCA Gene Therapy for Heart Failure: A Clinical Perspective.
Gene therapy has been applied to cardiovascular disease for over 20 years but it is the application to heart failure that has generated recent interest in clinical trials. There is laboratory and early clinical evidence that delivery of sarcoplasmic reticulum calcium ATPase 2a (SERCA2a) gene therapy is beneficial for heart failure and this therapy could become the first positive inotrope with anti-arrhythmic properties. In this review we will discuss the rationale for SERCA2a gene therapy as a viable strategy in heart failure, review the published data, and discuss the ongoing clinical trials, before concluding with comments on the future challenges and potential for this therapy.
1Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, SW3 6NP London, United Kingdom.
Carl
C
Hayward
2Royal Brompton and Harefield NHS Trust, Harefield Hospital, UB9 6JH Harefield, United Kingdom.
Nicholas R
NR
Banner
1Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, SW3 6NP London, United Kingdom.
Andrew
A
Morley-Smith
1Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, SW3 6NP London, United Kingdom.
Alexander R
AR
Lyon
3Imperial College London, SW3 6NP London, United Kingdom.
Sian E
SE
Harding
D000818:Animals; D002986:Clinical Trials as Topic; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics; D006333:Heart Failure / Q000235:genetics* / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D012107:Research Design; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases / Q000235:genetics* / Q000378:metabolism; D057170:Translational Research, Biomedical
D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases